Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences

Osimertinib, almonertinib and furmonertinib are third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) approved for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. This article reviews research advances in pharmacokinetics, pharmacodynamics, treatment-related adverse events, and other aspects related to the three EGFR-TKIs were systematically reviewed in order to provide references for clinical drug selection. There are differences in dosing schedule and incidence of adverse events among three drugs. Optimization of third-generation EGFR-TKIs options for individuals may produce the maximal benefits to NSCLC patients with EGFR T790M mutation.

Automated summary

This article reviews the research advances of three third-generation EGFR-TKIs, namely osimertinib, almonertinib, and furmonertinib, in terms of pharmacokinetics, pharmacodynamics, treatment-related adverse events, and other aspects. Individualized optimization of third-generation EGFR-TKIs options may provide maximum benefits to NSCLC patients with EGFR T790M mutation.